These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3911714)

  • 21. Investigations of ocular changes, extraocular muscle thickness, and eye movements in Graves' ophthalmopathy.
    Jankauskiene J; Imbrasiene D
    Medicina (Kaunas); 2006; 42(11):900-3. PubMed ID: 17172791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cyclosporin treatment of Basedow's ophthalmopathy].
    Dorey F; Strauch G
    Bull Soc Belge Ophtalmol; 1988; 226():65-70. PubMed ID: 3268308
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunologically mediated cytotoxicity against human eye muscle cells in Graves' ophthalmopathy.
    Wang PW; Hiromatsu Y; Laryea E; Wosu L; How J; Wall JR
    J Clin Endocrinol Metab; 1986 Aug; 63(2):316-22. PubMed ID: 3755139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extraocular muscle repositioning as the last therapeutic option for a patient with a severe course of Graves' Ophthalmopathy: a case report.
    Rau A; Klopfer M; Rommel N; Rau-Fornefeld M; Kolk A
    BMC Ophthalmol; 2018 Feb; 18(1):56. PubMed ID: 29482520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The differential diagnostic problems in unilateral euthyroid Graves' ophthalmopathy.
    Perrild H; Feldt-Rasmussen U; Bech K; Ahlgren P; Hansen JM
    Acta Endocrinol (Copenh); 1984 Aug; 106(4):471-6. PubMed ID: 6548073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
    Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
    Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upgaze intraocular pressure changes and strabismus in Graves' ophthalmopathy.
    Fishman DR; Benes SC
    J Clin Neuroophthalmol; 1991 Sep; 11(3):162-5. PubMed ID: 1836798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antioxidant agents in the treatment of Graves' ophthalmopathy.
    Bouzas EA; Karadimas P; Mastorakos G; Koutras DA
    Am J Ophthalmol; 2000 May; 129(5):618-22. PubMed ID: 10844053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between anti-human eye muscle antibodies and thyroid function, anti-TSH receptor antibodies and eye symptoms in Graves' ophthalmopathy.
    Molnár I; Balázs C
    Wien Klin Wochenschr; 1992; 104(24):744-7. PubMed ID: 1363165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Graves' ophthalmopathy with new immunosuppressive agents.
    Utech C; Wulle KG; Panitz N; Kiefer H
    Dev Ophthalmol; 1989; 20():94-9. PubMed ID: 2591632
    [No Abstract]   [Full Text] [Related]  

  • 33. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.
    Bartalena L; Marcocci C; Chiovato L; Laddaga M; Lepri G; Andreani D; Cavallacci G; Baschieri L; Pinchera A
    J Clin Endocrinol Metab; 1983 Jun; 56(6):1139-44. PubMed ID: 6341388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of orbital muscle changes evaluated by magnetic resonance imaging and thyroid-stimulating antibody in patients with Graves' ophthalmopathy.
    Nishikawa M; Yoshimura M; Toyoda N; Masaki H; Yonemoto T; Gondou A; Kato T; Kurokawa H; Furumura T; Inada M
    Acta Endocrinol (Copenh); 1993 Sep; 129(3):213-9. PubMed ID: 8105634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
    Molnár I
    Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose intravenous therapy with 7S immunoglobulins in autoimmune endocrine ophthalmopathy.
    Seppel T; Schlaghecke R; Becker A; Engelbrecht V; Feldkamp J; Kornely E
    Clin Exp Rheumatol; 1996; 14 Suppl 15():S109-14. PubMed ID: 8828957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism.
    Bartalena L; Marcocci C; Bogazzi F; Panicucci M; Lepri A; Pinchera A
    N Engl J Med; 1989 Nov; 321(20):1349-52. PubMed ID: 2811943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyroid surgery for Graves' disease and Graves' ophthalmopathy.
    Liu ZW; Masterson L; Fish B; Jani P; Chatterjee K
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010576. PubMed ID: 26606533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and significance of antibodies reactive with eye muscle membrane antigens in sera from patients with Graves' ophthalmopathy and other thyroid and nonthyroid diseases.
    Wu YJ; Clarke EM; Shepherd P
    Thyroid; 1998 Feb; 8(2):167-74. PubMed ID: 9510126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Muscle antigens recognized with autoantibodies in patients with Graves' ophthalmopathy].
    Adler G
    Endokrynol Pol; 1992; 43(1 Suppl):1-61. PubMed ID: 1345558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.